tbuckley/cabot-search huggingface dataset:
Abstract 4554: IL-17-CXCR2 axis promotes breast cancer metastasis and therapy resistance through facilitating recruitment of neutrophils
Authors: Lingyun Wu, Sugandha Saxena, Mohammad Awaji, Bhawna Sharma, Rakesh Singh
Journal: Cancer Research (2019)

Abstract Breast cancer is one of the most common cancer types that happens to global females. The major challenges for breast cancer include therapy resistance and metastasis. Various factors and cancer-related immune cells are involved in tumor chemotherapy resistance process, including pro-inflammatory cytokine, interleukin (IL) 17, CXCR2 ligands (pro-inflammatory chemokines) and neutrophils. They are the key players for promoting cancer progression, and numerous reports indicated them as a potential therapeutic target for various cancer types including breast cancer. However, the detailed mechanism(s) remains unclear. In the present study, we investigate the role of neutrophils in chemotherapy resistance and metastasis in breast cancer. In our previous study, we have observed increased levels of CXCR2 ligands in chemotherapy-resistant cells comparing with Cl66 parent cells. In this study, we observed upregulated IL17, IL17 receptor (IL-17R), granulocyte colony stimulating factor (GCSF) by qRT- PCR in resistant cells compared with parent cells. We further evaluated the protein levels of CXCR2 and its ligands, IL17 and its receptor, frequencies of neutrophils and T-helper 17 (Th17) cells in primary and metastatic tumors through using immunohistochemistry method. There were higher levels of IL17R, CXCR2, and CXCR2 ligands in metastatic tumor sites in comparison to the primary tumor sites. Moreover, we observed increased levels of IL17R, CXCR2, CXCR2 ligands together with the higher frequencies of neutrophils and Th17 cells in resistant tumors than Cl66 tumors. At the same time, tumor cells treated with IL-17 increased its proliferation rate and its expression of CXCL1 &amp; CXCL5; and the increase was all in a concentration-dependent manner. In addition, the increase of CXCR2 ligands by IL17 was inhibited when we treated the tumor cells with ERK and NF-KB signaling inhibitors, indicating both pathways are involved in the regulation of IL17-induced CXCR2 ligands secretion. Together, our data demonstrate an IL17-CXCR2 ligands axis plays protumorigenic inflammation, facilitating therapy resistance and metastasis through recruited neutrophils. Citation Format: Lingyun Wu, Sugandha Saxena, Mohammad Awaji, Bhawna Sharma, Rakesh Singh. IL-17-CXCR2 axis promotes breast cancer metastasis and therapy resistance through facilitating recruitment of neutrophils [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4554.
Errata
Authors: James Arnott, Henry Davies, Jonathan Pereira, George Macilwain, Richard Partridge, Benjamin Guy Babington, Benjamin Phillips, William Baly, Fred Le Gros, John Hennen, Riebard Quain, James Alderson, Thomas Mayo, Robert Nairn, William Sharpey, Leonard Stewart, Henry Ancell, Richard Blagden, George Busk, John Dalrymple, James Paget, J Bennett, R Turton, J Cleave, T Isaac, Edward Sankey, E Gavlard, G Dunn, J Gregory, G Macnamara, J Wilson, ; Dover, Robert Arthur, London Pedgrift, John Evans, Richard Thursday, :-John Pearse, Gateshead Edward, William Plews, Felix Louis, Napoleon De Larnd, Devonport Charles, William Bloxham, Halesowen Edwin, Thomas Watkins, R Died, Van Oatlands, F Diemen's Land, John Harding, Henry Morton, George Walker, Robert Brighton, India Company', Service March, Frankfort The-Maine, Ynyr Burges, Alexander Renton, Madeira March, Joseph Done, W Thomas, James Lately, Esq Kirkness, Regimen By
Journal: BMJ (1848)
Tar and nicotine delivery of cigarettes. What a difference a puff makes
Authors: L. T. Kozlowski
Journal: JAMA (1981)

WHEN smokers are asked what the tar and nicotine ratings of their cigarettes mean, they usually answer, "You know, it's what's in the cigarette." Even though much epidemiologic research and many health recommendations<sup>1,2</sup>have become dependent on the published tar and nicotine yields (to say nothing of the dependence of cigarette advertising on these figures), many researchers and health professionals appear to have no better understanding of these ratings than does the average smoker. Cigarettes do not deliver measured doses of tar and nicotine the way a capsule delivers a measured dose of a drug. A cigarette that has only a few small puffs taken on it produces small amounts of tar. Tar and nicotine delivery are highly correlated; for the sake of brevity, only tar yields will be discussed. Tar values were analyzed to the first decimal place but are reported here with no decimal places, as they
NEONATAL JAUNDICE
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2557: X-ray repair cross complementing 1 (XRCC1) is a critical factor in response to DNA damaging agents in triple negative breast cancer
Authors: Kevin J. Lee, Joel Andrews, Natalie R. Gassman
Journal: Cancer Research (2019)

Abstract Triple negative breast cancer (TNBC) is a breast cancer subtype that is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The lack of these targetable molecules makes cytotoxic chemotherapies a first-line choice, thus there is a pressing need to better understand how TNBC will respond to alternative or emerging treatments. Base excision repair (BER) proteins play an essential role in DNA damage response and repair, yet they have been overlooked in the analysis of chemotherapeutic treatment response. XRCC1 is a critical scaffold protein that mediates the protein-protein and protein-DNA interactions involved in BER and single-strand break repair. Several studies have linked single nucleotide polymorphisms (SNPs) within XRCC1 to increases in breast cancer incidence, yet XRCC1’s role in modulating treatment response is unknown. Here we show XRCC1 expression in a panel of TNBC cell lines correlates to an increase in basal DNA damage levels. DNA damage was analyzed using the Repair Assisted Damage Detection (RADD) assay which measures the broadest spectrum of DNA damage in vitro. We show MDA-MB-157 with low levels of XRCC1 correlate to low levels of basal DNA damage, MDA-MB-231 and HCC1806 have moderate levels of XRCC1 and DNA damage, and MDA-MB-468 contain high expression levels of XRCC1 that correlate with high levels of DNA damage. XRCC1 localization is also variable across the panel of TNBC cell lines with XRCC1 being mislocalized to the cytoplasm in the HCC1806 cells and highly localized to the nuclear compartment in the MDA-MB-468. These expression and localization changes in XRCC1 alter the ability of cells to repair single strand break (SSB) lesions induced by 355 nM laser microirradiation and DNA damaging chemicals. Here we show that TNBC cell lines respond differently to alkylating damage (methyl methanesulfonate) and PARP inhibition (olaparib) based on XRCC1 expression and localization in combination with levels of basal DNA damage. Taken together it is important to consider XRCC1 in context with DNA damage levels and expression of other BER proteins in TNBC in order to effectively design experiments utilizing DNA damaging agents or chemotherapeutics targeting DNA repair pathways. Citation Format: Kevin J. Lee, Joel Andrews, Natalie R. Gassman. X-ray repair cross complementing 1 (XRCC1) is a critical factor in response to DNA damaging agents in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2557.
DUELS BETTER FOUGHT IN THE EARLY MORNING.
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SUPPLY AND DEMAND
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).
Authors: Peter G. Ellis
Journal: Journal of Clinical Oncology (2016)

e18171 Background: Oncologists use Via Pathways (VP) to drive standardization to best evidence-based cancer care. VP include guidance for biomarker testing and associated treatments. Practices collaborated to analyze the first line non squamous carcinoma NSCLC VP. An unexpectedly large percentage of treatment decisions captured by oncologists in the VP portal had unknown ALK translocation or EGFR mutation test results. The VP was modified to require input of whether or not the test was ordered. This analysis examines the impact of this change. Methods: ALK and EGFR testing responses from the VP database were analyzed pre and post implementation of the change. Treatment decisions were reviewed to analyze prescribing patterns. Results: From 1/1/2014 to 1/29/2015, ~40% of EGFR or ALK testing responses were unknown. Post-implementation (1/30/2015 to 5/31/2015), 29.8% were charted as awaiting ALK results and 9.4% did not order the test; 29.5% were charted as awaiting EGFR results and 7.6% did not order the test. For the combined period, appropriate targeted agents were selected for 91.9% (n = 37) and 86.5% (n = 133) of patients who were ALK translocation positive and EGFR sensitizing mutation positive, respectively. Conclusions: The results in this example illustrate the ability of clinical pathways to promote testing of key biomarkers and drive to appropriate targeted agents. Frequent evaluation and modification of pathway content is required to ensure that practice patterns are accurately captured.
Insulin secretion in the diagnosis of adult-onset diabetes mellitus
Authors: R. W. Turkington
Journal: JAMA (1978)

The natural history of patients with glucose intolerance was observed in 334 patients during a period of 18 years. Glucose tolerance testing (100 g orally) was characterized by measurement of induced insulin secretion. Diabetic complications of retinopathy, sensory neuropathy, and renal disease developed only in the group of patients in whom the induced serum insulin peak fell below 60 μU/ml. Preservation of an insulin secretory reserve that permitted serum insulin peaks of 60 μU ml or greater was not associated with development of these complications or symptoms of insulin deficiency despite the presence of an equal degree of fasting hyperglycemia and glucose intolerance. A critical amount of insulin secretory reserve distinguishes between two qualitatively distinct clinical syndromes: true diabetes mellitus (the development of signs and symptoms of insulin deficiency) and the syndrome of pure resistance to insulin (signs and symptoms of hyperglycemia in the setting of adequate or excessive insulin secretion, frequently with obesity, but without diabetic complication). (<i>JAMA</i>240:833-836, 1978)
Duodenal Erosions
Authors: L. Walk
Journal: Endoscopy (1985)

Duodenal erosions may be classified as (1) Idiopathic erosions, a disease entity with a tendency to recur throughout a period of decades, and (2) Erosions as a stress reaction to various disorders. Massive bleeding may occur in both forms. It is of clinical interest that bleeding in a patient with duodenal erosions may not be from the duodenum but from concomitant stress haemorrhages in the upper part of the stomach. The natural history of duodenal erosions is reviewed, and 10 cases are analysed.
Twilight
Authors: Andrea A. Peterson
Journal: Annals of Internal Medicine (2008)

On Being a DoctorNovember 18, 2008TwilightAndrea A. Peterson, MDAndrea A. Peterson, MDFrom Norwalk Hospital, Norwalk, CT 06856.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-149-10-200811180-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail When I sit down on the side of the bed, I know. He has pale blue eyes and a careworn face, and I know that I will not make it home for dinner. I speak slowly and say, On the CT scan, there are multiple abnormal spots in your liver. A pause, then: It looks like the cancer has spread.His wife died several years ago, and their only son lives out of state, so for now it is just the 2 of us, talking quietly as the last of the late-afternoon sun filters through the blinds. For the moment, ... Author, Article, and Disclosure InformationAffiliations: From Norwalk Hospital, Norwalk, CT 06856.Corresponding Author: Andrea A. Peterson, MD, 24 Stevens Street, Norwalk Hospital, Norwalk, CT 06856. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics November 18, 2008Volume 149, Issue 10Page: 766KeywordsComputed axial tomographyEmotionsFallsGamesInfertilityLiverTouch ePublished: 18 November 2008 Issue Published: November 18, 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
NEW VIEWS ON THE PREDETERMINATION OF SEX
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Differences in death rates due to injury among blacks and whites, 1984
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of the Cigarette Brand Preferences of Adult and Teenaged Smokers—United States, 1989, and 10 US Communities, 1988 and 1990
Journal: JAMA (1992)

Tobacco use is the single most preventable cause of death in the United States (1). Approximately three fourths of adult regular smokers tried their first cigarette before the age of 18 years (National Institute on Drug Abuse [NIDA], 1988 NIDA Household Survey, unpublished data); about half had become regular smokers before their 18th birthday (2). Knowing what brands young smokers prefer may suggest what encourages them to smoke and may suggest smoking-prevention or smoking-cessation strategies (3-5). To determine brand preferences of smokers, data were reviewed from CDC's National Center for Health Statistics' 1989 Teenage Attitudes and Practices Survey (TAPS) and the National Cancer Institute surveys of adults in 1988 and 9th-grade students in 1990 in 10 U.S. communities* participating in the Community Intervention Trial for Smoking Cessation (COMMIT) evaluation (6). This report examines the findings of these surveys on the cigarette brand preferences of adult and teenaged smokers.
Juvenile Homicide
Authors: Carl C. Bell
Journal: JAMA (1990)

This book, which is actually a monograph, addresses the very narrow but important topic of juvenile homicide. The fact that juveniles arrested for homicide account for a small percentage of homicides (under 10%), and only a small proportion of these offenders are referred for a mental health evaluation, implies that the number of mental health clinicians and psychiatrists who would find this book useful in their practice will be limited. Despite this reality, by tackling the subject of adolescent homicide, which is the end point of adolescent aggression, the authors of the various chapters of the book give insight into lethal and nonlethal aggression of juveniles. Chapter 1 gives an excellent comprehensive review of the literature on the causes of juvenile homicide. Issues of major psychopathology, episodic dyscontrol or brief psychosis, brain dysfunction, psychodynamic factors, and preadolescent homicidal behaviors are covered. The author aptly notes that most studies on the
The Medical Register of New York, New Jersey and Connecticut for 1894-5.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multiple myeloma expressing CD19CD56 phenotype
Authors: Naohi Sahara, Michio Ihara, Takaaki Ono, Sadahiro Tamashima, Hirotaka Matsui, Akihiro Takeshita, Ryuzo Ohno
Journal: American Journal of Hematology (2000)

A 70-year-old woman presented with monoclonal gammopathy, pancytopenia, and renal insufficiency, which were initially refractory to combination chemotherapy by VMMD (vincristine, ranimustine, melphalan, and dexamethasone) and MP (melphalan and prednisolone) regimens. The myeloma cells, which consisted of 73% of bone marrow nucleated cells, expressed CD38+, CD19+, CD56−, CD45−, CD49e−, and MPC-1+ phenotypes by flow cytometric analysis and showed the rearranged immunoglobulin heavy chain (IgH) gene by Southern blotting. By immunostaining, the myeloma cells were positive for cytoplasmic immunoglobulin light chain κ. These results suggest that myeloma cells can express CD19+CD56−, the phenotype considered to be expressed on only normal plasma cells. Am. J. Hematol. 64:311–313, 2000. © 2000 Wiley-Liss, Inc.